【摘要】 呼吸道感染性疾病是临床最常见的流行性疾病之一，据统计，80%以上的急性上呼吸道感染是由病毒感染引起。近年来，新型冠状病毒感染大流行、流感病毒感染高发使呼吸道核糖核酸（RNA）病毒感染成为社会关注的焦点。小分子抗病毒药为目前备受关注的抗呼吸道病毒感染的治疗方案。为进一步促进抗呼吸道RNA病毒的小分子药物的合理应用，有效提高呼吸道RNA病毒药物治疗水平，山东省药学会循证药学专委会与山东省新冠病毒感染重症救治专家组联合，结合国内外最新研究成果，制订了《抗呼吸道RNA病毒的小分子药物应用专家意见》。更多还原

【Abstract】 Respiratory tract infection is one of the most common clinical epidemic diseases. According to statistics, more than 80% of acute upper respiratory tract infection is caused by virus infection. Recently,respiratory ribonucleic acid(RNA) virus infection has become the focus of attention due to the COVID-19pandemic and high incidence of influenza virus infection. Small molecular antiviral drugs are the currently recommended against respiratory viruses therapy. In order to further promote the rational use of small molecule drugs against respiratory RNA viruses and effectively improve the therapeutic efficacy of drugs against respiratory RNA viruses, the Expert Opinions on the Application of Small Molecule Drugs Against Respiratory RNA Viruses is formulated by the Specialized Committee of Evidence-Based Pharmacy of Shandong Pharmaceutical Association and the Expert Group on the Treatment of Severe COVID-19 Infection in Shandong Province based on the latest research results at home and abroad.更多还原